Movement Alert｜Kelun-Biotech Rises 3.08% in Regular Trading, Multiple Investment Banks Raise Target Prices Amid Institutional Buying Wave

Market Focus07-21

On July 21, Kelun-Biotech (06990.HK) rose 3.08% in regular trading, trading at 522.0 HKD/share, with turnover of approximately 66.88 million HKD. The move was driven by a wave of target price upgrades from major international investment banks alongside continued institutional accumulation.

On the news front, JPMorgan raised its target price for Kelun-Biotech to 648 HKD, citing positive research outcomes. Goldman Sachs lifted its target to 582.95 HKD while maintaining a Buy rating, raising the success probability for the Lung06 study from 81% to 90% and upgrading earnings estimates for fiscal years through 2028. UBS expressed optimism on the companys global expansion prospects. These upgrades followed the companys announcement that its core TROP2 ADC product sacituzumab tirumotecan combined with pembrolizumab met the primary endpoint in a Phase 3 study for first-line treatment of PD-L1-negative advanced non-squamous NSCLC, demonstrating significantly improved progression-free survival.

The stock has also benefited from broader institutional interest, with multiple leading public fund managers reportedly triggering disclosure thresholds in Hong Kong-listed innovative pharmaceutical names, underscoring sustained confidence in the sector.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment